{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:09:19Z","timestamp":1789524559130,"version":"build-2803163510"},"reference-count":44,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The assumption that more rapid treatment improves survival of advanced non-small cell lung cancer (NSCLC) has not yet been proven. We studied the relation between time-to-treatment and survival in advanced stage NSCLC patients in a large multicentric nationwide retrospective cohort. Additionally, we identified factors associated with delay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>We selected 10\u2009306 patients, diagnosed and treated between 2014 and 2019 for clinical stage III and IV NSCLC, from the Netherlands Cancer Registry that includes nationwide data from 109 Dutch hospitals. Associations between survival and time-to-treatment were tested with Cox proportional hazard regression analyses. Time-to-treatment was adjusted for multiple covariates including diagnostic procedures and type of therapy. Factors associated with delay were identified by multilevel logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Risk of death significantly decreased with longer time-to-treatment for stage III patients receiving only radiotherapy (adjusted HR, aHR &gt;21 days: 0.59 (95% CI 0.48 to 0.73)) or any type of systemic therapy (aHR &gt;49 days: 0.72 (95% CI 0.56 to 0.91)) and stage IV patients receiving chemotherapy and\/or immunotherapy (aHR &gt;21 days: 0.81 (95% CI 0.73 to 0.88)). No significant association was found for stage III patients treated with chemoradiotherapy and stage IV patients treated with targeted therapy. More complex diagnostic procedures often delay treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although in general it is important to start treatment as early as possible, our study finds no evidence that a more rapid start of treatment improves outcomes in advanced stage NSCLC patients. The benefit of urgent treatment is probably confounded by unmeasured patient and tumour characteristics and, clinical urgency dictating timelines of treatment. Time-to-treatment and its impact should be continuously evaluated as therapeutic strategies continue to evolve and improve.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/thoraxjnl-2021-218059","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T05:19:25Z","timestamp":1651123165000},"page":"467-475","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study"],"prefix":"10.1136","volume":"78","author":[{"given":"Sosse E","family":"Klarenbeek","sequence":"first","affiliation":[{"name":"Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke J","family":"Aarts","sequence":"additional","affiliation":[{"name":"Research and Development, Dutch Association of Comprehensive Cancer Centres, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Prokop","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Tummers","sequence":"additional","affiliation":[{"name":"Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga C J","family":"Schuurbiers","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"2025073109050650000_78.5.467.1","unstructured":"ACS . Cancer facts and figures 2020. American cancer Society, 2020."},{"key":"2025073109050650000_78.5.467.2","unstructured":"NKR, Incidentie longkanker . Nederlandse Kanker Registratie, 2020."},{"key":"2025073109050650000_78.5.467.3","first-page":"453","article-title":"Delays during the diagnostic evaluation and treatment of lung cancer","volume":"10","author":"Chandra","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025073109050650000_78.5.467.4","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, us setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol"},{"key":"2025073109050650000_78.5.467.5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"2025073109050650000_78.5.467.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"2025073109050650000_78.5.467.7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/tlcr.2019.04.14","article-title":"Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2025073109050650000_78.5.467.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3493"},{"key":"2025073109050650000_78.5.467.9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31818020eb"},{"key":"2025073109050650000_78.5.467.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.06.010"},{"key":"2025073109050650000_78.5.467.11","unstructured":"DCS . Wachttijden Zorg in Het Ziekenhuis. Dutch cancer Society, 2017."},{"key":"2025073109050650000_78.5.467.12","unstructured":"SONCOS . Multidisciplinaire normering oncologische zorg in Nederland, 2018."},{"key":"2025073109050650000_78.5.467.13","unstructured":"Ministerie van Volksgezondheid . Maximaal aanvaardbare wachttijden (Treeknormen), 2014."},{"key":"2025073109050650000_78.5.467.14","unstructured":"NVALT . Niet kleincellig longcarcinoom: Landelijke richtlijn versie 2.3 [Non-small cell lung carcinoma: National guideline version 2.3. Oncoline, 2015."},{"key":"2025073109050650000_78.5.467.15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2019.05.023","article-title":"Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands","volume":"134","author":"van de Ven","year":"2019","journal-title":"Lung Cancer"},{"key":"2025073109050650000_78.5.467.16","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318217b623"},{"key":"2025073109050650000_78.5.467.17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s12094-010-0606-5","article-title":"Effect of delays on survival in patients with lung cancer","volume":"12","author":"Gonz\u00e1lez-Barcala","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"2025073109050650000_78.5.467.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126608"},{"key":"2025073109050650000_78.5.467.19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.21037\/tlcr-19-675","article-title":"Impact of time-to-treatment on overall survival of non-small cell lung cancer patients-an analysis of the National cancer database","volume":"9","author":"Anggondowati","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025073109050650000_78.5.467.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.04.010"},{"key":"2025073109050650000_78.5.467.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-216865"},{"key":"2025073109050650000_78.5.467.22","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.12.123"},{"key":"2025073109050650000_78.5.467.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12992-020-00553-8","article-title":"Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review","volume":"16","author":"Nwagbara","year":"2020","journal-title":"Global Health"},{"key":"2025073109050650000_78.5.467.24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0659"},{"key":"2025073109050650000_78.5.467.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.06.126"},{"key":"2025073109050650000_78.5.467.26","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.clon.2017.07.012","article-title":"Treatment variation of sequential versus concurrent chemoradiotherapy in stage III non-small cell lung cancer patients in the Netherlands and Belgium","volume":"29","author":"Walraven","year":"2017","journal-title":"Clin Oncol"},{"key":"2025073109050650000_78.5.467.27","unstructured":"Mihaela Ene EAL , Blue GL , Bell BA . Multilevel models for categorical data using SAS\u00ae proC GLIMMIX: the basics. SAS global forum proceedings, 2015."},{"key":"2025073109050650000_78.5.467.28","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170070"},{"key":"2025073109050650000_78.5.467.29","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.12688\/f1000research.11902.1","article-title":"Advancing psychosocial care in cancer patients","volume":"6","author":"Grassi","year":"2017","journal-title":"F1000Res"},{"key":"2025073109050650000_78.5.467.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.12.006"},{"key":"2025073109050650000_78.5.467.31","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp13X675197"},{"key":"2025073109050650000_78.5.467.32","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/sj.bjc.6605384","article-title":"Do diagnostic delays in cancer matter?","volume":"101 Suppl 2","author":"Neal","year":"2009","journal-title":"Br J Cancer"},{"key":"2025073109050650000_78.5.467.33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.21037\/apm.2017.10.02","article-title":"Longevity after radiotherapy of stage III lung cancer: superior vena cava obstruction is associated with early mortality","volume":"7","author":"Ampil","year":"2018","journal-title":"Ann Palliat Med"},{"key":"2025073109050650000_78.5.467.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.685"},{"key":"2025073109050650000_78.5.467.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-06738-z","article-title":"Real-World treatment and survival of patients with advanced non-small cell lung cancer: a German retrospective data analysis","volume":"20","author":"Hardtstock","year":"2020","journal-title":"BMC Cancer"},{"key":"2025073109050650000_78.5.467.36","doi-asserted-by":"publisher","DOI":"10.1177\/1758834010397569"},{"key":"2025073109050650000_78.5.467.37","first-page":"393","article-title":"Utilization of molecular testing and survival outcomes of treatment with first- or second-line tyrosine kinase inhibitors in advanced non-small cell lung cancer in a Dutch population","volume":"38","author":"Sluga","year":"2018","journal-title":"Anticancer Res"},{"key":"2025073109050650000_78.5.467.38","doi-asserted-by":"publisher","DOI":"10.1177\/1758834013492001"},{"key":"2025073109050650000_78.5.467.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2015.08.002"},{"key":"2025073109050650000_78.5.467.40","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/JTO.0000000000000022","article-title":"Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients","volume":"9","author":"Nakamura","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2025073109050650000_78.5.467.41","unstructured":"Kuijpers CCHJ , Van den Heuvel MM , Overbeek LIH . Landelijke variatie in moleculaire diagnostiek bij gemetastaseerde longkanker. Nederlands Tijdschrift voor Geneeskunde 2019;163."},{"key":"2025073109050650000_78.5.467.42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143641","article-title":"A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses","volume":"13","author":"Koopman","year":"2021","journal-title":"Cancers"},{"key":"2025073109050650000_78.5.467.43","unstructured":"IKNL . Kankerzorg in beeld: gemetastaseerde kanker, 2020."},{"key":"2025073109050650000_78.5.467.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.07.032"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2021-218059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T16:05:34Z","timestamp":1753977934000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2021-218059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/thoraxjnl-2021-218059"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2021-218059","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,21]]}}}